SYSTEM AND METHOD FOR CELL CHARACTERISATION IN BIOLOGICAL TISSUE
20230023897 · 2023-01-26
Assignee
- The University Court Of The University Of Glasgow (Glasgow, GB)
- The University Court Of The University Of Edinburgh (Edinburgh, GB)
Inventors
- John Richard MERCER (Glasgow, GB)
- Steven NEALE (Glasgow, GB)
- Anubhav BUSSOOA (Glasgow, GB)
- Daniel HOARE (Glasgow, GB)
- Nosrat MIRZAI (Glasgow, GB)
- Jakub CZYZEWSKI (Glasgow, GB)
- Michael HOLSGROVE (Glasgow, GB)
- Srinjoy MITRA (Edinburgh, GB)
- Andreas TSIAMIS (Edinburgh, GB)
- Jamie MARLAND (Edinburgh, GB)
Cpc classification
A61B5/0002
HUMAN NECESSITIES
A61B5/4836
HUMAN NECESSITIES
A61B5/0537
HUMAN NECESSITIES
International classification
A61B5/0537
HUMAN NECESSITIES
A61B5/00
HUMAN NECESSITIES
Abstract
A system that provides the ability to integrate both diagnostic tissue detection and therapeutic tissue treatment functionality in an implantable medical device (IMD), such as a graft or stent. The system comprises: an IMD having a pair of electrodes configured to contact biological tissue at an implant location; an impedance sensor configured to detect data indicative of a complex impedance of the biological tissue at the electrodes for a plurality of frequencies; and an analysis device configured to determine one or more cell types in the biological tissue using information indicative of variation in phase and magnitude of the complex impedance across the plurality of frequencies. The system may include a signal generator for applying a treatment signal to the same electrodes.
Claims
1. A system for cell characterisation in biological tissue, the system comprising: an implantable medical device, IMD, comprising a plurality of sensing elements configured to interact with biological tissue at an implant location; an impedance sensor configured to: apply a sensing AC signal to the plurality of sensing elements, vary a frequency of the AC signal across a detection range; and detect data indicative of a complex impedance of the biological tissue at the plurality of sensing elements for a plurality of frequencies in the detection range; and an analysis device configured to: receive the detected data from the impedance sensor; and determine one or more cell types in the biological tissue using information indicative of variation in phase and magnitude of the complex impedance across the plurality of frequencies.
2. The system of claim 1, wherein the impedance sensor forms part of the IMD.
3. The system of claim 1, wherein the analysis device is configured to compare the detected data to stored signature data representative of one or more known cell types.
4. The system of claim 3, wherein the stored signature data includes complex impedance spectra data indicative of a variation in phase and magnitude of complex impedance across the plurality of frequencies for each known cell type.
5. The system of claim 4, wherein the complex impedance spectra data comprises information indicative of an evolution over time of complex impedance properties for each known cell type.
6. The system of claim 3, wherein the stored signature data includes a peak-to-peak difference in phase angle change for each known cell type.
7. The system of claim 1, wherein the analysis device is configured to determine one or more cell types in the biological tissue using both phase and magnitude information in the detected data.
8. The system of claim 3, wherein the one or more known cell types comprise a smooth muscle cell type and an endothelial cell type.
9. The system of claim 1 further comprising a signal generator for applying a treatment signal to the plurality of sensing elements, wherein the signal generator forms part of the IMD.
10. The system of claim 9, wherein the IMD comprises a housing that contains the impedance sensor, the signal generator, and a controller arranged to configure the system to operate in either a sensing mode or a treatment mode.
11. The system of claim 1 further comprising a communication module configured for bi-directional communication with the analysis device.
12. The system of claim 1, wherein the plurality of sensing elements comprise a pair of interdigitated comb electrodes.
13. The system of claim 1, wherein the plurality of sensing elements comprises multiple pairs of electrodes configured to contact the biological tissue at multiple regions of the implant location.
14. The system of claim 1, wherein the IMD is an intravascular device.
15. The system of claim 1, wherein the analysis device is a remote device in wireless communication with the impedance sensor.
16. A method of characterising cells in biological tissue, the method comprising: applying, by an impedance sensor, a sensing AC signal to a plurality of sensing elements in an implantable medical device, IMD, wherein the plurality of sensing elements are configured to interact with biological tissue at an implant location, varying a frequency of the sensing AC signal across a detection range; detecting, by the impedance sensor, data indicative of a complex impedance of the biological tissue at the plurality of sensing elements for a plurality of frequencies in the detection range; and determining, by an analysis device in communication with the impedance sensor, one or more cell types in the biological tissue using information indicative of variation in phase and magnitude of the complex impedance across the plurality of frequencies.
17. The method of claim 16 including comparing, by the analysis device, the detected data with stored signature data representative of one or more known cell types.
18. The method of claim 16, wherein the step of determining one or more cell types in the biological tissue uses both phase and magnitude information in the detected data.
19. The method of claim 18, wherein the one or more known cell types comprise a smooth muscle cell type and an endothelial cell type.
20. The method of claim 16 further comprising applying a treatment signal to the pair of electrodes to cause cell damage.
Description
Summary of the Figures
[0042] Embodiments and experiments illustrating the principles of the invention will now be discussed with reference to the accompanying figures in which:
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
DETAILED DESCRIPTION OF THE INVENTION
[0056] Aspects and embodiments of the present invention will now be discussed with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
[0057]
[0058] The lower part of
[0059] The sensor 200 comprises a housing 202 connected to a pair sensing elements, which in this example comprise a pair of interdigitated comb electrodes 204, which are configured in a substantially cylindrical shape to conform to an inner surface of the graft/vessel interface. The housing 202 comprises a controller 208, which includes a microprocessor configured to control operation of the sensor 200 according to computer readable instructions stored on a memory (not shown). The controller 208 is operable to effect three primary functions: (1) impedance sensing, (2) therapeutic treatment, and (3) two-way communication (e.g. to reporting sensed information and/or to receive information about required treatment). The housing 202 thus includes a signal generator 206 that operates to apply an AC voltage signal to the electrodes 204. When operating in a diagnostic mode, the controller 208 is configured to sweep a frequency of the voltage signal and detect complex impedance at the electrodes. Complex impedance is a vector quantity. Herein, unless the context indicates otherwise, we use the term “impedance” to refer to the magnitude of the complex impedance and the term “phase” to refer to its direction.
[0060] Based on the detected results, the controller 208 may be configured to generate spectra that represent the variation in both the magnitude and phase of impedance with frequency. The type of tissue growing on the electrodes can be determined by monitoring changes in these spectra over time. This determination may be done remotely or locally. For example, the spectra may be communicated to an external unit for analysis, or the controller 208 may be configured to analyse them in situ.
[0061] To achieve communication, the housing 202 includes a communication unit 210 and antenna 212 configured to communicate with the external device 214 using any appropriate wireless protocol. A short range protocol such as Bluetooth® may be used.
[0062] There now follows a detailed explanation of various experiments that demonstrate the functionality of the system set out above.
[0063]
[0064] In the following experiments, two types of interdigitated electrodes (IDEs) were used.
[0065] In one set of experiments, the electrodes were patterned on a glass microscope slide with a 10 nm titanium adhesion layer and 100 nm gold layer. However, it is also possible to fabricate the electrodes using other standard microfabrication techniques, e.g. using platinum on a silicon substrate.
[0066] In the experiments, it was also desirable to observe the surface of the IDE. Accordingly, the IDE were mounted in a temperature and CO.sub.2 controlled enclosure 106, where they were observable via a live cell microscope 108 (Olympus IX71, Japan), that was in communication with the computer 102.
[0067] In use, the IDEs 104 were connected to the LCR meter 112 for impedance measurements and to the function generator 110 for applying controlled voltages to achieve therapeutic effects (e.g. electroporation).
[0068] The fabricated device was sterilized by misting with 70% ethanol and washing with deionized water. Baseline impedances were first measured with a culture medium only. The LCR meter 112 was configured in a fixed current (10 μA), varying voltage mode to measure impedance. The impedances were measured at 10, 20, 30, 40, and 50 kHz for both the large IDE and small IDE.
[0069] An adherent primary vascular cell type, mouse aortic smooth muscle cells (MASMCs), was used for a first batch of experiments. The cells were cultured in phenol red free DMEM media supplemented with 10% fetal bovine serum (FBS) in cell culture flasks. Once sub-confluent, the cells were trypsinized and 200,000 MASMCs were then seeded into the fabricated device, and the cell suspension was pipetted a few times to ensure a homogeneous population was plated. MASMCs were spherical when in suspension and spindle-shaped, once adhered to the culture substrate. The cells were allowed to settle down for 18 h inside an incubator (37° C. and 5% CO.sub.2) to ensure that they adhered to the electrodes. Experimental impedances were then recorded. The increases in impedance were calculated at each frequency for the large and small IDEs. Bright field imaging and impedance measurements (at 10 kHz) were simultaneously started and acquired at 15 min intervals. At the 20 h time point, the LCR meter 112 was disconnected from the electrodes, and the function generator 110 was connected so as to apply a treatment signal, which in this example was a sine voltage of 2 V.sub.peak-to-peak 40 kHz for 2 min, the minimum duration required to observe a drop in impedance.
[0070] The impedance readings obtained in the first period were thus independent of the applied voltage from the function generator. In contrast, changes in impedance after the treatment signal was applied were directly due to changes in the cellularity across the sensor surface.
[0071] Following application of the treatment signal, the function generator 110 was disconnected and the LCR meter 112 reconnected so as to continue impedance measurements up to the 45 h timepoint and comparisons made between the small IDE and large IDE. To provide a positive control for comparing the effects of electromediated cell death (apoptosis), the chemotherapeutic drug etoposide and a mechanical scratch were used. Etoposide is a chemotherapy drug used to treat cancer. It prevents cell proliferation by inhibiting a class of DNA repair enzymes called Topoisomerase II. Its use in the study was purely to act as a drug based positive control to induce the controlled form of cell death (apoptosis). Equally the mechanical scratch assay was a physical insult to the cell monolayer that would induce both uncontrolled necrotic and apoptotic death.
[0072]
[0073] The ratio of the mean increase with small IDE over large IDE had a mean value of 4.35. This suggests the relationship between mean increase in impedance detected due to MASMCs is inversely proportional to the electrode area.
[0074]
[0075] The large IDE detected an increase of ˜15 Ω when the cells had settled down while the small IDE detected a maximum increase of ˜150 Ω. After the application of the voltage, the impedance dramatically dropped by 15Ω for the large IDE and by 160Ω for the small IDE. In both cases, the impedance dropped approximately back to the baseline impedance detected at Ωh. Following this drop, the impedance did not go back up to the pre-voltage impedance, implying that the voltage causes a permanent effect on the cells. However, any physical effect across the on the cells were not immediately observable using bright-field microscopy. Moreover, the effects seemed to be restricted to the regions in-between the electrode fingers rather than on the fingers. The cells around the IDE appeared mostly unaffected by the application of the voltage. This indicates that a very specific and localized effect can be applied to a cell monolayer.
[0076]
[0077] Fluorescent live cell imaging was used to assess the effects across the monolayer more precisely. To mimic the effects of mechanical damage that might be expected during stent deployment to the vasculature a scratch assay was compared to a drug induced form of cell death and used as a positive control for the subsequent experiments. Etoposide (a topoisomerase inhibitor of DNA repair) was used in the drug-induced positive control.
[0078]
[0079] The percentages were compared using one-way ANOVA with Tukey's multiple comparison posthoc test. For the negative control, the percentage of apoptotic cells at the endpoint was statistically different (p<0.05) from the baseline, implying that there was an important increase in apoptosis from 8% to 18%. Comparing the pre-voltage treatment at baseline to the etoposide drug positive control post-treatment highlighted a statistically difference in the percentages of live and apoptotic cells by the endpoint (p<0.001 and p<0.001, respectively). This implies that the induction of apoptosis using the treatment signal had similar effects to the application of 50×10.sup.−6 m etoposide at 24 h. The percentage of apoptosis induced by the voltage was higher (46% vs 36%) compared to etoposide. Hence, a short pulse of voltage can induce a higher percentage apoptosis in a MASMC monolayer compared to a prolonged exposure to etoposide.
[0080]
[0081] In these experiments, Mouse Aortic Smooth Muscle Cells (MASMC) and immortalised murine endothelial cells (sEND1) were used. The cells were cultured in DMEM media (Sigma Aldrich, UK) supplemented with 10% Foetal Bovine Serum in culture flasks. Once sub-confluent, the cells were trypsinised and 400,000 cells were then seeded into the fabricated device, and the cell suspension was pipetted up and down a few times to ensure a homogeneous population was plated. Pure MASMC populations, pure sEND1 populations and coculture (1:1 ratio) were used in separate experiments. The large IDE and small IDE were present within the same cell chamber. Thus, the same cell monolayer covered both the large IDE and the small IDE.
[0082] The microfabricated cell chambers were sterilised by misting with 70% ethanol and rinsing with deionised water. The LCR meter was used in the constant current (CC) mode, with the current set at 10 μA. The baseline impedance spectra for the frequency range 10 Hz to 1 MHz were first measured with DMEM culture medium only. Then, 400,000 cells were seeded into the chambers and allowed to adhere to the bottom (glass+ electrodes) of the chambers for 18 h, inside an incubator (37° C. and 5% CO.sub.2). Then the experimental impedance spectra, with the cells, were acquired.
[0083] In order to compare between the large IDE and small IDE, the impedance was normalised to impedance per unit area. As complex impedance is a vector quantity, only the magnitude of the impedance is dependent on the area of the electrode while the phase is independent of the area of the electrode. Hence, normalisation was carried out by dividing the magnitude of the impedance by the area of the respective electrodes and keeping the phase constant.
[0084] The impedance spectra were recorded using the LCR meter with 3 technical replicates (3 microfabricated chambers) for the 3 cell populations (MASMCs, sEND1 and co-culture).
[0085] The graphs shown in
[0088] For the MIPUA vs Frequency plots, the AUC increase was calculated by subtracting the AUC of the “culture medium only” curve from the AUC of the “culture medium+ cells” curve. The AUC increase was compared between different pairs of cell populations and electrode types using Oneway ANOVA.
[0089] For the large IDE (
[0090] Within the optimum frequency range, the experimental impedance spectra is higher than the baseline impedance spectra, for both the large IDE and small IDE, indicating an increase in impedance due to cell adhering to the electrodes. AUC analysis shows that impedance increase detected by the small IDE, compared to large IDE, is significantly higher for all of MASMC, sEND1 and co-culture. This implies that, for the same cell monolayer, the small IDE can detect a higher increase in impedance per unit area compared to the large IDE. Thus, miniaturising the IDE increases its detection capability. At equal cell densities, the impedance increase detected by SIDE was significantly higher for MASMC compared to sEND1 and for co-culture compared to sEND1. The impedance increase detected by the large IDE was not significantly different for any of the cell populations. This indicates that the small IDE can detect differences in the impedance magnitude increase generated by equal cell densities.
[0091] Thus, EIS measured using the small IDE provides a way of characterising vascular cell monolayers.
[0092]
[0093] In these further experiments, a setup corresponding to that shown in
[0094] In more detail, silicon-based sensors was seeded with 50,000 mouse aorta smooth muscle cells (MASMC) or 50,000 immortalised mouse endothelial cells (MEC) or a control of media only. Impedance and phase measurements were then made from 0-24 hours at 6 hour intervals.
[0095]
[0096] MASMCs and MECs were increased compared to the control and MASMCs had a greater impedance than MECs. Performing area under the curve (AUC) analyses for the impedances across the 1 kHz-1 MHz sweep yields the graph shown in
[0097] However, it may be recognised that impedance magnitude can increase independently of cell type. For example, this may occur due to the number of cells or multiple layers of cells. Therefore, although impedance magnitude gives a basic understanding of cell type, impedance could be used more so as a way of quantifying the number of cells or even depth of cells in ISR. Thus, for reliable cell characterisation it is desirable to use a second measurement component to corroborate the impedance magnitude findings of cell type and quantity.
[0098] Using the phase angle of the impedance as a combined interpretative tool provides such corroboration and thus enables detection between phenotypically different cells.
[0099] Similar to impedance magnitude, it is possible to analyse the phase angle over the whole frequency and compare the groups using one-way ANOVA.
[0100] Additional information in cell type can be gleaned by looking at peak-to-peak differences in phase angle trends shown in
[0101] The experiment discussed above demonstrate the feasibility of using an implantable medical device (IMD) that comprises a stent or graft with an integrated impedance sensor for cell characterisation. The impedance sensor may be configured to communicate with an extravascular transceiver, e.g. in a wearable device or portable smartphone or tablet, which in the future may form part of a central node for IMDs as part of a wireless body area network. The wireless connection from the IMD allows data from the SMART stent sensor to be sent to a secure cloud server, potentially connecting through a smartphone, or by some other transceiver unit. This extravascular transceiver will be capable of two-way communication to allow for both secure data transmission but also receiving of data, such as therapeutic care plans from physicians, changes in reading parameters or simply to send a data reading on demand.
[0102] Although described above in the context of enabling the assessment of ISR in a stent (or a similar wound responses in a graft), the system may also be employed to determine cell types in a variety of other applications, as discussed briefly below: [0103] Atherosclerosis, where fibro-fatty plaques block coronary arteries. Symptoms of chronic ischemic angina can progress to acute myocardial infarction and stoke. If the plaque ruptures or erodes it initiates an occlusive thrombotic or embolic event. [0104] Percutaneous coronary intervention (PCI), which is a procedure in which a patient diagnosed with an arterial blockage has an expandable metal stent deployed to the coronary vasculature to restores blood flow. These inert devices themselves damage the wall of the vessel that results in a hyper-proliferative response termed restenosis that can re-occlude the vessel. Self-reporting stents that include miniaturised versions of the proposed device would be efficacious in the treatment of these conditions. [0105] Renal dialysis, which requires long-term vascular access. Haemodialysis filters impurities in the patients' blood when their kidney's fail. A dialysis machine returns the cleaned blood but requires venous catheterisation to pass the blood back into the patient. These short-term entry sites and longer-term arteriovenous (AV) fistula or AV graft fibrosis and block from stenosis without warning and vessel patency is lost. In long term dialysis patient when this occurs the patient may succumb to their diagnosis. Detection of vascular remodelling at these sites could be determined by the proposed device. [0106] Chemotherapy, where patients require drugs or nutrition to be administered directly into the blood stream. A central venous catheter (CVC) often termed central venous access devices or central lines may be placed for many months or years. These external lines are referred to as PICC lines may block and need reposition, removal and re-implantation and benefit from the proposed device. [0107] Stroke, which is a neurological debilitating condition in which the blood supply to the brain is blocked. Ischaemic stroke occurs in which a deficit of oxygen is caused by a thrombosis or emboli from an atherosclerotic plaque build-up, rupture or occlusive vessel disease termed intracranial stenosis, sometime exacerbated by hypertension. Detecting blood clots and preventing cerebral plaque rupture post stent deployment we be advantageous as currently there are no reporting technologies. [0108] Aneurysm, which is a weakening of the wall of an artery, e.g. in the brain's cerebral circulation or any high pressure artery throughout the vasculature. A weakness in the vessel wall can cause a bulge, distention, or fatal perforation. Often asymptomatic when they rupture will cause massive internal bleeding and delamination of layers of the artery such as in the aorta. The device discussed above may be incorporated as a cell and flow sensor into an endovascular repair device. [0109] Primary hypertension, which is caused be narrowing of the renal artery (renal stenosis) and can lead to uncontrollable high blood pressure and kidney failure. Current interventions involve renal stenting, which could benefit from the incorporation of the proposed device into renal stents and grafts. [0110] Biliary and Oesophageal stents. Biliary stents can treat biliary obstruction, which occurs when one of the ducts that carries bile from the liver to the intestines via the gallbladder becomes blocked If left untreated it can lead to serious complications including severe infection, septicaemia, and death. Oesophageal stents are routinely used to maintain patency of the throat after cancer. [0111] Stent malposition, where a stent is not closely aligned with the luminal surface of the vasculature. The proposed device can be used to detect the impedance signature of the wall and confirm appropriate alignment. [0112] Endovascular leak, which occurs where the implant damages the wall of the vessel leading to drop in blood flow that can promote clot formation and prove fatal. The proposed device could detect these changes in real-time and report for immediate attention. [0113] Infection detection, where bacterial and fungal growth on an implantable medical device could be detected by monitoring impedance. [0114] Central line canulation blockage, in which a hollow needle inserted into a vessel to provide a continuous path for blood flow and administration of drugs becomes blocked. The sensor described herein may be us to detect build-up of a potential blockage. [0115] Catheterisation fouling, where a hollow tube inserted into an open lumen suffers from overgrowth and blockage. The sensor described herein may be used as an early detection device. [0116] Biofilm detection, in which the sensor discussed herein can detect bacterial overgrowth that causes implantable and surface mounted devices to be fouled. [0117] Clinical drains, where hollow tubes are placed post-surgery to relieve blockages caused by air, blood, pus or build-up of fluids. They are placed ubiquitously for a number of other pathologies associated with inadequate drainage that are prone to clogging. Examples include chest drains, cysts drains, biliary and pancreatic surgery, thyroid, neurosurgery, urinary catheters, nasogastric tubes, orthopaedic procedures and after plastic surgery.
[0118] The features disclosed in the foregoing description, or in the following claims, or in the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for obtaining the disclosed results, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.
[0119] While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention.
[0120] For the avoidance of any doubt, any theoretical explanations provided herein are provided for the purposes of improving the understanding of a reader. The inventors do not wish to be bound by any of these theoretical explanations.
[0121] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0122] Throughout this specification, including the claims which follow, unless the context requires otherwise, the word “comprise” and “include”, and variations such as “comprises”, “comprising”, and “including” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0123] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment. The term “about” in relation to a numerical value is optional and means for example +/−10%.